OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
MBRX
Moleculin Biotech, Inc.
Common Stock
0.55
0.016
3.00%
Delayed (15 Min) Trade Data: 12:00am 07/11/2025
Business Description
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001659617
Fiscal Year End
12/31
Company Officers & Contacts
Not available
Board of Directors
Not available
Other Company Insiders
Not available
Service Providers
Not available
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US
Employees
Not Available
Shell
No
Products and Services
Not available
Company Facilities
Not available
Company Notes
12(k) Suspension for the period commencing at 9:30 a.m. EDT on May 4, 2020 and terminating at 11:59 p.m. EDT on May 15, 2020.
Loading...
Symbol
OTCM
Last
57.41
Change
0.41 (0.72%)
Bid
57.40
Ask
58.40
Volume
667
Time
00:00
